Bio

Besides teaching at Stanford, Mr. Rosen serves on the board of directors of: AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), where he served as CEO from 2015-17; Entrega, Inc.; Hammerton, Inc.; and, Kala Pharmaceuticals, Inc. (NASDAQ: KALA), where he served as Chairman from 2014-15.

Academic Appointments

  • Lecturer, Graduate School of Business

Administrative Appointments

  • Lecturer in Management, Gradaute School of Business (2011 - Present)
  • Lecturer, Department of Chemical Engineering (2009 - Present)
  • Lecturer, Department of Chemical Engineering (2000 - 2003)

Honors & Awards

  • Fellow, American Institute of Medical and Biological Engineers (AIMBE) (2014 - Present)
  • Member, National Academy of Engineering (2005 - Present)
  • Arjay Miller Scholar, Stanford Gradaute School of Business (1987)
  • Henry Ford II Scholar, Stanford Graduate School of Business (1987)

Boards, Advisory Committees, Professional Organizations

  • Joint Biomedical Engineering Department Industrial Advisory Board, University of North Carolina/North Carolina State (2015 - Present)
  • Biomedical Advisory Council, City College of New York (2005 - Present)
  • School of Engineering Advisory Council, Stanford University (2004 - 2007)
  • Advisory Council on Interdisciplinary Biosciences, Stanford University (2003 - 2011)

Professional Education

  • BS, Stanford University, Chemical Engineering (1980)
  • MS, Massachusetts Institute of Technology, Chemical Engineering (1982)
  • MBA, Stanford Graduate School of Business, Business (1987)

Patents

  • Patrick Wong, Howard Rosen, Nathan Roth, Phyllis Gardner. "United States Patent 6,333,050 Oral Delivery of Discrete Units", ALZA Corporation, Dec 25, 2001
  • Patrick Wong, Howard Rosen, Nathan Roth, Phyllis Gardner. "United States Patent 6,210,713 Oral Delivery of Discrete Units", ALZA Corporation, Apr 3, 2001
  • Patrick Wong, Howard Rosen, Phyllis Gardner, Nathan Roth. "United States Patent 6,106,845 Oral Delivery of Discrete Units", ALZA Corporation, Aug 22, 2000
  • Patrick Wong, Howard Rosen, Nathan Roth, Phyllis Gardner. "United States Patent 5,989,590 Oral Delivery of Discrete Units", ALZA Corporation, Nov 23, 1999
  • Patrick Wong, Howard Rosen, Phyllis Gardner, Nathan Roth. "United States Patent 5,780,058 Oral Delivery of Discrete Units", ALZA Corporation, Jul 14, 1998
  • Robert Langer, Howard Rosen, Robert Linhardt, Kam Leong. "United States Patent 4,906,474 Bioerodible Polyanhydrides for Controlled Drug Delivery", MIT, Mar 6, 1990
  • Robert Langer, Howard Rosen. "United States Patent 4,891,225 Bioerodible Polyanhydrides for Controlled Drug Delivery", MIT, Jan 2, 1990

Contact

  • Academic
    hrosen@stanford.edu
    University - Other Teaching/Research Department: Graduate School of Business - Faculty Position: Lecturer
    • Stanford Graduate School of Business
    • E257
    • Stanford,  California  94305 
    University - Other Teaching/Research Department: Graduate School of Business - Academic Administrations Position: Lecturer

Additional Info

  • Mail Code: 4800
  • Other Names:
    Howie Rosen

Links

Current Research and Scholarly Interests

Mr. Rosen is interested in the unique aspects of entrepreneurship as it relates to engineering and science-based industries as well as all types of startups in developing economies.

Research Interests
Entrepreneurship
Biotechnology
Pharmaceuticals
Clean Tech
Energy
Developing Economies

Teaching Statement
There are many common themes in the challenges faced by entrepreneurs; my teaching focuses on helping students understand and experience the unique aspects of entrepreneurship as it relates to engineering and science-based industries as well as all types of startups in developing economies.

2024-25 Courses

All Publications

  • The rise and rise of drug delivery NATURE REVIEWS DRUG DISCOVERY Rosen, H., Abribat, T. 2005; 4 (5): 381–85

    Abstract

    Drug delivery has typically focused on optimizing marketed compounds, improving their effectiveness or tolerability, and simplifying their administration. This role now includes the first biopharmaceuticals as well as more conventional drugs. As drug-delivery technologies come into play earlier in the development cycle, however, they can also enhance the screening and evaluation of new compounds and 'rescue' failed compounds, such as those with low solubility. In this article, we look back at how the burgeoning field of drug delivery came into being and describe approaches for future discovery and development.

    View details for DOI 10.1038/nrd1721

    View details for Web of Science ID 000229297900018

    View details for PubMedID 15864267

  • BIOERODIBLE POLYANHYDRIDES FOR CONTROLLED DRUG DELIVERY BIOMATERIALS ROSEN, H. B., CHANG, J., WNEK, G. E., LINHARDT, R. J., LANGER, R. 1983; 4 (2): 131–33

    View details for DOI 10.1016/0142-9612(83)90054-6

    View details for Web of Science ID A1983QQ00800013

    View details for PubMedID 6860755